SPRO vs. YS, HOOK, QTTB, IFRX, AFMD, ONCY, SLS, ETON, BTAI, and CMRX
Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include YS Biopharma (YS), Hookipa Pharma (HOOK), Q32 Bio (QTTB), InflaRx (IFRX), Affimed (AFMD), Oncolytics Biotech (ONCY), SELLAS Life Sciences Group (SLS), Eton Pharmaceuticals (ETON), BioXcel Therapeutics (BTAI), and Chimerix (CMRX). These companies are all part of the "pharmaceutical preparations" industry.
YS Biopharma (NASDAQ:YS) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.
Spero Therapeutics has a net margin of 21.98% compared to Spero Therapeutics' net margin of 0.00%. YS Biopharma's return on equity of 38.54% beat Spero Therapeutics' return on equity.
Spero Therapeutics received 199 more outperform votes than YS Biopharma when rated by MarketBeat users. However, 100.00% of users gave YS Biopharma an outperform vote while only 69.20% of users gave Spero Therapeutics an outperform vote.
Spero Therapeutics has higher revenue and earnings than YS Biopharma.
YS Biopharma has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
In the previous week, YS Biopharma had 4 more articles in the media than Spero Therapeutics. MarketBeat recorded 6 mentions for YS Biopharma and 2 mentions for Spero Therapeutics. YS Biopharma's average media sentiment score of 0.80 beat Spero Therapeutics' score of 0.24 indicating that Spero Therapeutics is being referred to more favorably in the news media.
52.6% of YS Biopharma shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 4.5% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
YS Biopharma presently has a consensus target price of $5.25, suggesting a potential upside of 574.11%. Spero Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 387.33%. Given Spero Therapeutics' higher probable upside, equities analysts clearly believe YS Biopharma is more favorable than Spero Therapeutics.
Summary
Spero Therapeutics beats YS Biopharma on 11 of the 15 factors compared between the two stocks.
Get Spero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spero Therapeutics Competitors List
Related Companies and Tools
